Search results
Results from the WOW.Com Content Network
Hepatic veno-occlusive disease (VOD) or veno-occlusive disease with immunodeficiency is a potentially life-threatening condition in which some of the small veins in the liver are obstructed. It is a complication of high-dose chemotherapy given before a bone marrow transplant or excessive exposure to hepatotoxic pyrrolizidine alkaloids .
The liver damage can consist of damage to liver cells, hepatic sinusoidal syndrome (obstruction of the veins in the liver), cholestasis (where bile does not flow from the liver to the intestine) and liver fibrosis. [127] [128] Nephrotoxicity (kidney damage) can be caused by tumor lysis syndrome and also due direct effects of drug clearance by ...
The leading cause of liver cancer is cirrhosis due to hepatitis B, hepatitis C, or alcohol. [4] Other causes include aflatoxin, non-alcoholic fatty liver disease and liver flukes. [3] The most common types are HCC, which makes up 80% of cases and intrahepatic cholangiocarcinoma. [3]
Prolonged use of temozolomide can cause loss of fertility, pneumonia and, in rare cases, secondary cancer and liver damage. Law firm Brabners is representing 14 patients who received the drug ...
Hepatocellular carcinoma (HCC [1]) is the most common type of primary liver cancer in adults and is currently the most common cause of death in people with cirrhosis. [2] HCC is the third leading cause of cancer-related deaths worldwide.
These drugs can cause cardiovascular problems, bleeding problems, stomach problems, liver damage, and kidney damage. Gels are typically the preferred format, as they have fewer side effects but ...
Hepatic arterial infusion (HAI) is a medical procedure that delivers chemotherapy directly to the liver.The procedure, mostly used in combination with systemic chemotherapy, plays a role in the treatment of liver metastases in patients with colorectal cancer (CRC). [1]
Unlike chemotherapy with its known toxicity towards normal body systems, Namodenoson provides protective effects. Ramat Gan, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the European ...